Topical treatments in psoriasis: today and tomorrow

Clinics in Dermatology

Volumn 26, Issue 5, 2008, Pages 432-437

  Bos, Jan D ^a   Spuls, Phyllis I ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADAPALENE; AMCINONIDE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL; CLOBETASONE BUTYRATE; DESONIDE; DESOXIMETASONE; DEXAMETHASONE; DIFLORASONE DIACETATE; DIFLUCORTOLONE VALERATE; DITHRANOL; FLUMETASONE PIVALATE; FLUOCINONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HALCINONIDE; HYDROCORTISONE ACETATE; MOMETASONE FUROATE; PIMECROLIMUS; RETINOL DERIVATIVE; TACROLIMUS; TAR; TAZAROTENE; ULOBETASOL PROPIONATE; UNINDEXED DRUG; UREA; VITAMIN D DERIVATIVE;

ARTICLE; ATOPIC DERMATITIS; CARCINOGENICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; ERYTHEMA; HUMAN; HYPERCALCEMIA; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NEUTROPHIL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SKIN ATROPHY; SKIN IRRITATION; T LYMPHOCYTE; TACHYPHYLAXIS; TELANGIECTASIA; TERATOGENICITY; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION;

ADMINISTRATION, CUTANEOUS; HUMANS; PSORIASIS;

EID: 49849092512     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.10.025     Document Type: Article

References (35)

1. Finlay A.Y., and Ortonne J.P. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg 8 (2004) 310-320
2. Mason J., Mason A.R., and Cork M.J. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 146 (2002) 351-364
3. Tremblay J.-F., and Bissonnette R. Topical agents for the treatment of psoriasis, past, present and future. J Cutan Med Surg 6 (2002) 8-11
4. Lebwohl M., Ting P.T., and Koo J.Y.M. Psoriasis treatment: traditional therapy. Ann Rheum Dis 64 Suppl II (2005) ii83-ii86
5. Van de Kerkhof P.C.M. The topical treatment of psoriasis. Clin Exp Dermatol 30 (2005) 205-208
6. Van de Kerkhof P.C.M., and Kragballe K. Recommendations for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 19 (2005) 495-499
7. Dando T.M., and Wellington K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am J Clin Dermatol 6 (2005) 255-272
8. Durakovic C., Ray S., and Holick M.F. Topical paricalcitol (19-nor-1a, 25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. Br J Dermatol 151 (2004) 190-195
9. Zonneveld I.M., Rubins A., Jablonska S., et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134 (1998) 1101-1102
10. Bos J.D., and Meinardi M.M.H.M. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9 (2000) 224-228
11. Scheinfeld N. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online J 10 (2004) 3
12. Mason A.R., Cork M.J., Dooley G., et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 1 (2006) CD005028
13. Afifi T., de Gannes G., Huang C., and Zhou Y. Topical therapies for psoriasis: evidence-based review. Can Fam Physician 51 (2005) 519-525
14. Gulliver W.P., and Donsky H.J. A report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experience with Mahonia aquifolium for the treatment of plaque psoriasis. Am J Ther 12 (2005) 398-406
15. McFerren M.A. Useful plants of dermatology: VIII. The false hellebore (Veratrum californicum). J Am Acad Dermatol 54 (2006) 718-720
16. Vali A., Asilian A., Khalesi E., et al. Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris. J Dermatol Treat 16 (2005) 234-237
17. Kragballe K., Gjertsen B.T., De Hoop D., et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 337 (1991) 193-196
18. Fenton C., and Plosker G.L. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol 5 (2004) 463-478
19. Schön M.P., and Boehncke W.H. Psoriasis. N Engl J Med 352 (2005) 1899-1912
20. In: Bos J.D. (Ed). Skin immune system (SIS): cutaneous immunology and clinical immunodermatology (2005), CRC Press, Boca Raton 824
21. Bos J.D., De Rie M.A., Teunissen M.B.M., and Piskin G. Psoriasis: activation of innate immunity. Br J Dermatol 152 (2005) 1098-1107
22. Balbi A., Anzaldi M., Mazzei M., et al. Synthesis and biological evaluation of novel heterocyclic ionone-like derivatives as anti-inflammatory agents. Bioorg Med Chem 14 (2006) 5152-5160
23. White P.J., Atley L.M., and Wraight C.J. Antisense oligonucleotide treatments for psoriasis. Expert Opin Biol Ther 4 (2004) 75-81
24. Raoof A.A., Chiu P., Ramtoola Z., et al. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci 93 (2004) 1431-1439
25. Schäcke H., Rehwinkel H., Asadullah K., and Cato A.C.B. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic address. Exp Dermatol 15 (2006) 565-573
26. Buttgereit F., Burmester G.R., and Lipworth B.J. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 365 (2005) 801-803
27. Schoepe S., Schäcke H., May E., and Asadullah K. Glucocorticoid therapy induced skin atrophy. Exp Dermatol 15 (2006) 406-420
28. Ma Y., Khalifa B., Yee Y.K., et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 116 (2006) 892-904
29. Guenther L.C. Optimizing treatment with topical tazarotene. Am J Clin Dermatol 4 (2003) 197-202
30. Njar V.C., Gediya L., Purushottamachar P., et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 14 (2006) 4323-4340
31. Schiller M., Metze D., Luger T.A., et al. Immune response modifiers-mode of action. Exp Dermatol 15 (2006) 331-341
32. Gilliet M., Conrad C., Geiges M., et al. Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 140 (2004) 1490-1495
33. Cristofaro P., and Opal S.M. Role of Toll-like receptors in infection and immunity: clinical implications. Drugs 66 (2006) 15-29
34. Kumar S., Boehm J., and Lee J.C. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2 (2003) 717-726
35. Lin T.H., Metzger A., Diller D.J., et al. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther 318 (2006) 495-502